Factors Determining Cognitive Dysfunction in Cerebral Small Vessel Disease

Vinod Varghese1, Sadanandavalli Retnaswami Chandra1, Rita Christopher2

  • 1Department of Neurology, National Institute of Mental Health and Neurosciences, Bengaluru, Karnataka, India.

Insights

Hypertension and high homocysteine levels correlate with white matter changes in small vessel disease. However, these factors, along with CYP11B2 gene variations, do not predict progression to vascular dementia.

Area of Science:

  • Neurology
  • Genetics
  • Geriatrics

Background:

  • Vascular dementia involves cognitive decline from cerebrovascular injury.
  • Small vessel disease (SVD) is common in older adults, but not all develop dementia.
  • Identifying factors predicting dementia progression in SVD is crucial for targeted interventions.

Purpose of the Study:

  • To investigate genetic and non-genetic factors associated with cognitive impairment in patients with radiological SVD.
  • To determine if specific comorbidities or CYP11B2 gene polymorphisms predict the conversion of SVD-related white matter changes to dementia.

Main Methods:

  • A prospective study included 210 patients meeting SVD criteria.
  • Data collected included medical comorbidities, demographics, substance abuse, and neuropsychological evaluations.
  • Genetic testing for CYP11B2 polymorphisms (TT, TC, CC alleles) was performed.

Main Results:

  • Hypertension and hyperhomocysteinemia significantly correlated with white matter changes severity.
  • No significant correlation was found between cognitive dysfunction and white matter changes severity or CYP11B2 genotypes.
  • TC genotype was more prevalent in male hypertensives; however, no studied factor predicted leukoaraiosis progression to dementia.

Conclusions:

  • While hypertension and hyperhomocysteinemia are linked to white matter changes in SVD, they do not appear to drive the progression to vascular dementia.
  • CYP11B2 gene polymorphisms (TT, TC, CC) were not found to be determinants in the conversion of leukoaraiosis to dementia.
Abstract

Related Concept Videos

Dementia01:30

Dementia

Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
672
Cognitive Development During Adulthood01:30

Cognitive Development During Adulthood

Cognitive development continues throughout adulthood, undergoing significant shifts across early, middle, and late stages. Individual transition occurs from adolescent idealism to pragmatic and adaptable thinking in early adulthood. During this period, individuals learn to integrate personal beliefs with the recognition that other perspectives are equally valid. Exposure to the complexities of modern society, diverse experiences, and higher education contribute to this adaptive thought process,...
1.1K
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists01:30

Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists

Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
813
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
2.0K